The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting.
What biological, technical, ethical, and medical hurdles must be overcome for regenerative medicine to make traditional organ transplantation redundant?
Biological Hurdles : There have been complicated biological mechanisms that are challenging to understand in organ regeneration. Deciphering the complication that drives the differentiation of cells, formation of tissues, and host integration is integral. Managing and maintaining the immune response is also a significant hurdle (Hoogduijn, Montserrat, and Laan).
Technical Hurdles : Differentiation cannot be controlled during regeneration. Cellular reprogramming technology needs modification to set the foundation for precision and protection. Large-scale production of organs is also a technical hurdle, especially when moving from the laboratory (Hoogduijn, Montserrat, and Laan).
Ethical Considerations : Cell sourcing is one of the critical aspects. There may be an unethical use of cells. Thus, ethical guidelines and protocols must be streamlined and optimized to make this whole process ethical and responsible (Hoogduijn, Montserrat, and Laan). The most important thing is to maintain informed decisions (consent) regarding the use of the cells. Of course, the process requires transparency to justify liability.
Medical Challenges : There may be issues in clinical efficacy. Regenerative therapies should be aligned with practical design and control. Effective measures related to safety must be maintained to get approval and validate acceptance in the medical domain. Making regenerative medicine a new standard is possible, but it requires excessive collaboration between clinicians, researchers, and regulatory bodies. The combination of safe and consistent execution of therapies is essential (Hoogduijn, Montserrat, and Laan).
Industry Evolution: Steering the transition from research to commercialization is essential to justify evolution. Secure funding, appropriate business models, and effective compliance are part of the evolution. Apart from that, production, distribution, and management should be aligned with adequate infrastructure. Cellular production must adhere to the best manufacturing protocols. There is also a need to evade hurdles as far as access is concerned. Consistent engagement with healthcare providers, insurance entities, and regulatory bodies is a way to move forward and justify evolution (Kang).
Work Cited
Hoogduijn, Martin J., et al. "The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy andOrgan Regeneration Section meeting." Transplant International 33 (2020): 833–840.
Kang, Y James. "Regenerative Medicine Research: striving to better serve the emerging field." Regenerative Medicine Research 4.1 (2016).
